


tDESCRIPTION

Description	Recombinant Human Coronavirus SARS-CoV-2 Spike Protein S1 subunit, Receptor-Binding Domain (RBD), variant 501Y.V3, Lineage B.1.1.248 (P1, 20J/501Y.V3, Brazil & Japan)
Sequence	Native NCBI Accession Number: MN908947
	Arg319-Phe541, with mutation K417T; E484K; N501Y
Expression system	HEK293 cells
Тад	HIS Tag C-Terminus
Purification	Affinity chromatography
Extinction coefficient	35340 M-1.cm-1 Abs 0.1% (=1 g/l) 1.35 assuming all pairs of Cys residues form cystines
Predicted Molecular Weight	26.1 kDa

SPECIFICATIONS

SDS Page	Approx. 32 kDa
Concentration	1 mg/ml
Purity	>95% by SDS PAGE gel
Formulation	Liquid PBS
Activity	Recognized by CR3022 anti RBD recombinant antibody and Covid-19 positive patients serum samples.
Stability and Storage	Store at minimum -20°C. Avoid repeated freeze-thaw cycles

DATA



Rec SARS-CoV-2 RBD variant 501Y.V3 Lineage B.1.1.248 715-H22-0BU



Diaclone S.A.S. 6, rue Dr. Jean-François-Xavier Girod BP1985 – 25000 Besançon – France SIRET 451 377 006 00015 – TVA FR69451377006

Tel. : +33 (0)3 81 41 38 38 Fax. : +33 (0)3 81 41 36 36 Email : info@diaclone.com www.diaclone.com Version 2 06/05/2021

Diaclone, une société du groupe



SARS-CoV-2 Spike Glycoprotein (S1) RBD variant 501Y.V3 Lineage B.1.1.248

Spike protein (S protein) is one of four structural proteins of Coronavirus (SARS-Cov, SARS-Cov-2, MERS amongst other), S protein plays the most important role in viral attachment, fusion and entry, and it serves as a target for development of antibodies, entry inhibitors and vaccines.

In the S protein, the Receptor Binding Domain (RBD) mediates viral entry of SARS-Cov and SARS-Cov-2 into host cells by its interaction with the membrane receptor ACE2 (Angiotensin-converting enzyme 2).

This variant 501Y.V3 also named P1 (20J/501Y.V3) of SARS-CoV-2 was first identified in Japan on early January 2021 detected in four travelers from Brazil, and rapidly declared to be circulating in Brazil.

Products Manufactured and Distributed by: Diaclone SAS 6 Rue Dr Jean-François-Xavier Girod BP 1985, 25020 Besançon Cedex France Tel +33 (0)3 81 41 38 38 Fax +33 (0)3 81 41 36 36 Email: <u>info@diaclone.com</u> www.diaclone.com

Rec SARS-CoV-2 RBD variant 501Y.V3 Lineage B.1.1.248 715-H22-0BU



Diaclone S.A.S. 6, rue Dr. Jean-François-Xavier Girod BP1985 – 25000 Besançon – France SIRET 451 377 006 00015 – TVA FR69451377006

Tel. : +33 (0)3 81 41 38 38 Fax. : +33 (0)3 81 41 36 36 Email : info@diaclone.com Version 2 06/05/2021

Diaclone, une société du groupe